Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers M > Headlines for MyoKardia, Inc. > News item |
MyoKardia registers $86.25 million of stock for initial public sale
Credit Suisse, Cowen, BMO, Wedbush PacGrow will assist with offering
By Devika Patel
Knoxville, Tenn., Sept. 28– MyoKardia, Inc. will price its initial public sale of common stock with a 30-day greenshoe, according to a Form S-1 filed Monday with the Securities and Exchange Commission. The company has registered up to $86.25 million of stock.
Credit Suisse Securities (USA) LLC and Cowen and Co. are the bookrunners. BMO Capital Markets is the lead manager, and Wedbush PacGrow is the co-manager.
Proceeds will be used for clinical development, preclinical, discovery and research programs, research and development activities, working capital and other general corporate purposes.
The South San Francisco, Calif., biopharmaceutical company seeks to treat serious and neglected rare cardiovascular diseases. The company intends to list its common stock on the Nasdaq stock exchange under the symbol “MYOK.”
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.